CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34 + hematopoietic stem/progenitor cells

Yiqi Yang; Bihui Zhang; Junye Xie; Jingsheng Li; Jia Liu; Rongzhan Liu; Linhao Zhang; Jinting Zhang; Zijian Su; Fu Li; Leisheng Zhang; An Hong; Xiaojia Chen

doi:10.3724/abbs.2023047

CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34 ⁺ hematopoietic stem/progenitor cells

Acta Biochim Biophys Sin (Shanghai). 2023 Oct 25;55(10):1630-1639. doi: 10.3724/abbs.2023047.

Authors

Yiqi Yang^{1

2}, Bihui Zhang¹, Junye Xie¹, Jingsheng Li¹, Jia Liu², Rongzhan Liu¹, Linhao Zhang¹, Jinting Zhang¹, Zijian Su¹, Fu Li¹, Leisheng Zhang^{3

4}, An Hong^{1

2}, Xiaojia Chen^{1

2}

Affiliations

¹ Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji'nan University, Guangzhou 510632, China.
² The First Affiliated Hospital, Ji'nan University, Guangzhou 510630, China.
³ Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province & NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou 730000, China.
⁴ Key Laboratory of Radiation Technology and Biophysics, Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei 230031, China.

Abstract

Umbilical cord blood (UCB) is an advantageous source for hematopoietic stem/progenitor cell (HSPC) transplantation, yet the current strategies for large-scale and cost-effective UCB-HSPC preparation are still unavailable. To overcome these obstacles, we systematically evaluate the feasibility of our newly identified CH02 peptide for ex vivo expansion of CD34 ⁺ UCB-HSPCs. We herein report that the CH02 peptide is specifically enriched in HSPC proliferation via activating the FLT3 signaling. Notably, the CH02-based cocktails are adequate for boosting 12-fold ex vivo expansion of UCB-HSPCs. Meanwhile, CH02-preconditioned UCB-HSPCs manifest preferable efficacy upon wound healing in diabetic mice via bidirectional orchestration of proinflammatory and anti-inflammatory factors. Together, our data indicate the advantages of the CH02-based strategy for ex vivo expansion of CD34 ⁺ UCB-HSPCs, which will provide new strategies for further development of large-scale HSPC preparation for clinical purposes.

Keywords: CD34 hematopoietic stem/progenitor cell; CH02 peptide; Fms-like tyrosine kinase receptor 3; umbilical cord blood; wound healing.

MeSH terms

Animals
Antigens, CD34
Cell Adhesion Molecules
Cells, Cultured
Diabetes Mellitus, Experimental*
Fetal Blood
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells
Mice
Peptides / pharmacology

Substances

Antigens, CD34
Cell Adhesion Molecules
Peptides

Grants and funding

This work was supported by the grants from the National Natural Science Foundation of China (Nos. 81902801, 82173729, 82273833 and 82260031), the Program of Department of Natural Resources of Guangdong Province (No. GDNRC [2021] 50), the Guangdong Provincial Key R&D Program (No. 2022B1111070007), the Guangdong Basic and Applied Basic Research Foundation (No. 2022A1515110620), the Science & Technology Program of Guangzhou City (No. 20212210007), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2019PT320005), and the 2021 Central-Guided Local Science and Technology Development Fund (No. ZYYDDFFZZJ-1).